Cantor Fitzgerald Remains a Hold on CRH Medical Corporation

By Austin Angelo

In a report released today, Joseph France from Cantor Fitzgerald maintained a Hold rating on CRH Medical Corporation (NYSEArca: CRHM), with a price target of $3. The company’s shares opened today at $2.80.

France observed:

“Revenue and earnings were slightly below our estimates, reflecting a lack of acquisitions in 4Q17. CRHM completed one acquisition in late March 2018, and we expect to see the benefits in 2Q18.”

According to TipRanks.com, France is a 4-star analyst with an average return of 8.5% and a 52.1% success rate. France covers the Services sector, focusing on stocks such as Cross Country Healthcare, Five Star Quality Care, and Envision Healthcare.

CRH Medical Corporation has an analyst consensus of Moderate Buy, with a price target consensus of $4.

See today’s analyst top recommended stocks >>

The company has a one-year high of $6.40 and a one-year low of $1.46. Currently, CRH Medical Corporation has an average volume of 85.42K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

CRH Medical Corp. provides physicians with innovative products for the treatment of gastrointestinal diseases. It focuses on physician education, patient outcomes and patient awareness. The company’s product, the CRH ORegan System, is a single use, disposable, hemorrhoid treatment.